Sugi Predict

Sugi Predict / Compounds / SCHEMBL2095212

SCHEMBL2095212

SCHEMBL2095212

CC(C)(C)OC(=O)N1CCCC2CNCC21

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NR1H2 P55055 1/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ PREP P48147 1/20 0.38
▸ UCHL1 P09936 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17053036 1.00 HSD17B10 (0.45) HSD17B10SMN1; SMN2NR1H2NR1H3NPC1
SCHEMBL1982884 1.00 HSD17B10 (0.45) HSD17B10SMN1; SMN2NR1H2NR1H3NPC1
SCHEMBL3789080 1.00 HSD17B10 (0.45) HSD17B10SMN1; SMN2NR1H2NR1H3NPC1
SCHEMBL1983358 1.00 HSD17B10 (0.45) HSD17B10SMN1; SMN2NR1H2NR1H3NPC1
SCHEMBL6983332 1.00 HSD17B10 (0.45) HSD17B10SMN1; SMN2NR1H2NR1H3NPC1
SCHEMBL23654034 1.00 HSD17B10 (0.45) HSD17B10SMN1; SMN2NR1H2NR1H3NPC1
SCHEMBL18428250 0.96 NR1H2 (0.43) HSD17B10SMN1; SMN2NR1H2NR1H3NPC1
SCHEMBL1135308 0.91 GPR119 (0.39) HSD17B10NR1H2NR1H3HPGD
SCHEMBL3697263 0.91 GPR119 (0.39) HSD17B10NR1H2NR1H3HPGD
SCHEMBL2411163 0.91 GPR119 (0.39) HSD17B10NR1H2NR1H3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104507938-B Preparation method of 1-cyclopropyl-7- (S, S-2, 8-diazo-bicyclo [4.3.0] nonane-8-yl) -6-fluoro-8-methoxy-1, 4-dihydro-4-oxo-3-quinoline carboxylic acid 娜塔莉亚·米克拉维娜·德卡奇 2017-02-15 — — CN claimed
EP-3867248-B1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-12-10 — — EP disclosed
US-12448363-B2 Kinase inhibitors VIDYA THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250115587-A1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LIMITED (GB) 2025-04-10 — — US disclosed
CN-115867346-B Kinase inhibitors GB005股份有限公司 2025-03-14 — — CN disclosed
US-12234227-B2 Pyrazole derivatives as H4 antagonist compounds NXERA PHARMA UK LIMITED (GB) 2025-02-25 — — US disclosed
US-20250059182-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS, INC 2025-02-20 — — US disclosed
EP-2895488-B1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS MERCK SHARP & DOHME LLC (US) 2024-12-11 — — EP disclosed
CN-112939967-B Pyrazolo [1,5-a ] pyridine compound, and preparation method and application thereof 深圳众格生物科技有限公司 2024-08-27 — — CN disclosed
CN-114787161-B Pyrazolo [1,5-a ] pyridine compound, and preparation method and application thereof 深圳众格生物科技有限公司 2024-08-02 — — CN disclosed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 — — US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 — — EP disclosed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 — — WO disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 — — US disclosed
US-20020049212-A1 Benzimidazole compounds as ORL1-receptor agonists PFIZER PRODUCTS INC. 2002-04-25 — — US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 — — US disclosed
EP-1122257-A1 Benzimidazole compounds as ORL1-receptor agonists PFIZER INC. (US) 2001-08-08 — — EP disclosed
US-5654318-A 1-HALOCYCLOPROPYL-3-CARBOXY-4-OXO-7-(2,8-DIAZOBICYCLO(4.3.0)-NON-8-YL)QUINOLINES; POTENT MICROBIOCIDES; NONTOXIC; REDUCED LIPOPHILICITY DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1997-08-05 — — US disclosed
CN-1095068-A Bicyclic amine derivatives DAIICHI SEIYAKU CO (JP) 1994-11-16 — — CN disclosed
EP-0603887-A2 Bicyclic amine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1994-06-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234227-B2 Pyrazole derivatives as H4 antagonist compounds HRH4, HRH3, HRH2 HSD17B10 1416/4885SMN1; SMN2 4592/4885NR1H2 137/4885
US-12448363-B2 Kinase inhibitors BTK, ABL1, LYN HSD17B10 4212/4885SMN1; SMN2 4070/4885NR1H2 3402/4885
US-20020049212-A1 Benzimidazole compounds as ORL1-receptor agonists OPRL1, ORMDL3, OGFRL1 HSD17B10 2259/4885SMN1; SMN2 2926/4885NR1H2 73/4885
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 HSD17B10 1786/4885SMN1; SMN2 4744/4885NR1H2 1429/4885
US-20250059182-A1 SOS1 INHIBITORS SOS1, SOS2, SOST HSD17B10 3792/4885SMN1; SMN2 1762/4885NR1H2 347/4885
US-20250115587-A1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS HRH4, HRH3, HDAC3 HSD17B10 1359/4885SMN1; SMN2 3906/4885NR1H2 136/4885
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A HSD17B10 3418/4885SMN1; SMN2 4514/4885NR1H2 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.